Global Cell Free DNA Isolation and Extraction Market :

Cell-free DNA are non-encapsulated DNA that enters the bloodstream during apoptosis or necrosis. This cell-free DNA is cleared by macrophages during normal body functioning, but overproduction of cells during cancer produces extra cfDNA in the blood. The CfDNA are found in blood, plasma, serum, or other body fluids and holds clinical significance in diagnosis, monitoring, and detection of various non-invasive diseases. The cfDNA is a screening method for tumors and other fetal DNA studies, they are challenging to extract as they are found in small quantities, and so reliable and consistent methods are required to isolate the less abundant cell-free DNA with higher sensitivity as they have a half-life of about two hours. The global cfDNA extraction and isolation industry is a multi-billion-dollar market which consists of multitudinous companies involved in the development of cfDNA extraction/isolation kits and automated instruments based on various sequencing platforms such as NGS and PCR to bolster the increasing demand for non-invasive screening tests and procedures.

cfDNA extraction and isolation products include extraction/isolation kit, automated instruments, and other consumables to improve the overall non-invasive screening process efficiency. Cell-free DNA testing is a new and efficient technology in which free-flowing DNA fragments from a liquid sample such as saliva, urine, and blood from patients are analyzed to screen a condition or disease. Cell-free DNA testing is essential solutions for the medical diagnostic companies that are facing increasing level of demand for high productivity and cost reduction. The recent advances in Cell-free DNA testing have paved the way for the development of multiple advanced technologies to aid in the battle against cancer and various other diseases including genetic and infectious diseases. The advent of screening procedures such as NIPT and liquid biopsy with improved efficiency of screening results are the most prominent factors facilitating the growth of Cell-free DNA testing in the medical diagnostic industry. Furthermore, these advanced testing procedures have also enabled the companies in the medical diagnostic industry to meet the regulatory compliance as well as manage their profit margins and remain competitive in the market.

The purpose of this study is to gain a holistic view of the Cell-free DNA testing market in terms of various influencing factors, such as recent trends and technological advancements. The scope of this report constitutes an in-depth study of the global Cell-free DNA testing market, including a thorough analysis of the products across different regions. The market has been segmented into ‘product’, ‘platform’, ‘application ‘and ‘regions’. The report presents the reader with an opportunity to unlock comprehensive insights concerning the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global Cell-free DNA testing market with the help of the key factors driving the market, restraints that can inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities and challenges) and industry analysis as well.

The research study considers the market share analysis for a comprehensive understanding of the global Cell-free DNA testing market and assesses the factors governing the same. Growth share matrix and detailed pricing analysis have been included in the report. The market by region has been further sub-segmented into various countries, and in each sub-segment, the key market trends, list of the key players, and the recent developments that have taken place have been discussed.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges and opportunities in the Cell-free DNA testing market?
•    What was the market value of the leading segments and sub-segments of the global Cell-free DNA testing in 2016?
•    How will each segment of the global Cell-free DNA testing market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2026?
•    What are the influencing factors that may affect the market share of the key players in Cell-free DNA testing market?
•    How will the Cell-free DNA testing industry evolve during the forecast period 2018- 2026?
•    What are the key developmental strategies that are being implemented by the key players to sustain in this market?
•    What is the market share of each of the companies by NIPT test providers?
•    What is the growth-share matrix of each of the companies by NIPT test providers?
•    Who are the key players in the Cell-free DNA extraction/isolation kits market and what are their contributions?
•    What are the major benefits of the implementation of Cell-free DNA testing in the different field of applications including cancer diagnosis, prenatal testing, and several other chronic diseases?
•    What is the scope of Cell-free DNA testing in the emerging economies of the Asia Pacific and Latin America?
•    What is the scope for expansion by the key players of the Cell-free DNA testing market in the Asia Pacific and Latin America?

The key players who have been contributing significantly to the Cell-free DNA testing market include Agilent Technologies, Inc., Berry Genomics, BGI Diagnostics, BioCAT GmbH, F. Hoffmann-La Roche AG, GATC Biotech AG., Illumina, Inc., Laboratory Corporation of America, LifeCodexx AG, Merck KGaA, Natera Inc., NIPD Genetics, Norgen Biotek Corp., PreAnalytiX GmbH, Premaitha Health Plc, QIAGEN, Quest Diagnostics, SeraCare Life Sciences, Inc., STRATEC Biomedical AG, Thermo Fisher Scientific, AccuBioMed, Aline Biosciences, BioChain, Bioo Scientific Corporation, COVARIS, INC., Epigentek Group Inc., NeoGenStar LLC, Omega Bio-tek, Inc, Promega Corporation, System Biosciences, LLC., and STRECK, INC.,  among others.